Glaxosmithkline

This study tests a new drug called bepirovirsen in about 857 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if bepirovirsen can achieve a functional cure, meaning the virus is suppressed and no longer detectable after stopping al…

This study tests a new drug called bepirovirsen to see if it can cure chronic hepatitis B. About 981 adults who are already on standard antiviral therapy will receive either bepirovirsen or a placebo for 24 weeks, then stop all hepatitis B treatments to see if the virus stays sup…

This early-stage study tests an experimental mRNA vaccine designed to protect against respiratory syncytial virus (RSV). Around 213 healthy adults aged 18-45 will receive different doses to check safety and immune response. The goal is to find a well-tolerated dose for future lar…

This study is testing a vaccine called MenB+OMV NZ to see if it is safe and helps protect healthy infants in Korea from meningococcal group B disease, a serious cause of meningitis. About 50 babies will receive two doses starting at 2 months old, plus a booster shot later. Resear…

This study tests new mRNA-based flu vaccines in about 971 healthy adults aged 18 and older. The goal is to see if these vaccines are safe and trigger a strong immune response against seasonal flu. Participants receive the vaccine and are monitored for side effects and antibody le…

This study tests a new vaccine called Pn-MAPS30plus that may protect against more types of pneumonia bacteria than current vaccines. About 127 healthy adults aged 50 to 64 will receive the vaccine or a control to check safety and immune response. The goal is to see if the vaccine…

This study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses to find the best vacc…

This study looks at the best time to give a second dose of the RSV vaccine to adults aged 60 and older. It also checks how long protection from a single dose lasts over up to five RSV seasons. About 10,000 participants from a previous study will take part, and those who received …

This study is testing a new vaccine called MenABCWY that aims to protect against five types of meningitis bacteria (A, B, C, W, and Y) in one shot. About 312 healthy teenagers will receive the vaccine on different schedules to check for safety and how well their immune system res…

This study tests new mRNA-based seasonal flu vaccines in 776 healthy adults aged 18 and older. The goal is to see how well the vaccines trigger an immune response and whether they are safe. Participants will be monitored for side effects like pain, fever, and fatigue. The vaccine…

This study tests a combination of two drugs, belantamab mafodotin and feladilimab, in about 25 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goals are to check safety and find the best dose. This is not a cure, …

This early-phase study tests a new drug, belantamab mafodotin, added to standard medications (bortezomib, lenalidomide, dexamethasone) for adults newly diagnosed with multiple myeloma. About 118 participants will receive different schedules of the new drug to find the safest and …

This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to see how the drug behaves in the body and if it is safe when used with standard treatments. About 25 children will take part, and the study lasts 68 weeks.

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. The study involv…

This early-stage study tests a new drug called remzistotug in 152 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to check the drug's safety and how the body processes it, both alone and with other cancer drugs. Participants must…

This study tests whether combining different immunotherapies works better than one alone for people with a type of head and neck cancer that has come back or spread. The trial includes 316 adults whose tumors have a specific marker (PD-L1 positive) and who have not had prior trea…

This study tests a drug called dostarlimab in 23 Chinese patients with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. The goal is to see if the drug can make the cancer disappear completely and stay gone for at least 12 months. Patients r…

This study tests a new drug called belantamab mafodotin against a standard combination therapy (pomalidomide plus dexamethasone) in 325 adults with multiple myeloma that has returned or stopped responding to prior treatments. Participants are randomly assigned to receive either t…

This early-phase study tests a new experimental drug called GSK6097608, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 107 adults will take pa…

This study tests a new drug called bepirovirsen in 157 adults who have both HIV and chronic hepatitis B and are already on stable HIV treatment. The goal is to see if bepirovirsen can clear hepatitis B virus from the blood better than a placebo. Participants continue their regula…

This study compares two drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets belantamab mafodotin plus standard drugs, the other gets daratumumab plus standard drugs. The goal is to see which combo works better at…

This study gives people with myelofibrosis, a rare bone marrow cancer, continued access to the experimental drug momelotinib. It aims to check the drug's long-term safety and see how it affects survival. Participants are already taking momelotinib in earlier studies and have not …

This study tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard treatment for people with multiple myeloma that has come back or stopped responding to therapy. About 494 adults with this blood cancer will be ra…

This early-phase study tests a new oral drug (GSK4524101) alone and with another drug (niraparib) in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and to see if the combination shrinks tumors. About 42…

This phase 3 study tests a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) against a standard combination (daratumumab plus bortezomib and dexamethasone) in 72 Chinese participants whose multiple myeloma has returned or stopped responding to prior tr…

This study tests whether the immunotherapy drug dostarlimab alone can eliminate tumors in people with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. About 154 participants will receive the drug and be closely monitored. If the cancer disa…

This study tests a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to find the safest dose and see how well the comb…

This study tests a combination of two drugs, belantamab mafodotin and isatuximab, in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to find the safest and most effective dose and see how well the combination c…

This study tests a new long-lasting medicine called GSK5784283 for adults aged 18 to 75 whose asthma is not well controlled despite regular treatments. The medicine blocks a protein called TSLP that can cause airway inflammation. The trial has two parts: Part A finds the best dos…

This study tests whether a triple-combination inhaler (FF/UMEC/VI) works better than the usual two-medication inhalers (ICS/LABA) for adults whose asthma is not well controlled. About 1,366 participants will be followed for up to 52 weeks to measure lung function and symptom cont…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how well …

This early-phase study tests a new experimental drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effec…

This study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The drug aims to shrink tumors by blocking a DNA repair protein. The trial will check safety, side effects, and how well the drug work…

This study tests whether adding two immunotherapy drugs (cobolimab and dostarlimab) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. About 758 participants whose cancer worsened after prior treatments will be randomly assigne…

This study tests an experimental drug called GSK4527226 in 367 people with early Alzheimer's (mild memory or thinking problems). Participants receive either a low dose, a high dose, or a placebo as an IV infusion. The goal is to see if the drug can slow down worsening of memory a…

This study tests a drug called belantamab mafodotin, alone or with other cancer drugs, in people with multiple myeloma that has come back or stopped responding to treatment. About 208 adults who have already tried at least three other treatments will take part. The goal is to see…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of two drugs—belantamab mafodotin and nirogacestat—to see if they are safe and can shrink or control the cancer. About 106 adults wil…

This study tests an experimental drug called GSK4532990 in 284 adults with NASH (a type of fatty liver disease) and advanced liver scarring. The goal is to see if the drug can improve liver scarring and reduce inflammation without making the disease worse. Participants will recei…

This study tests whether a new combination of two drugs (belrestotug and dostarlimab) is safer and works better than the current standard treatment (pembrolizumab) for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 88 adults …

This study is testing new combinations of immunotherapy drugs in people with advanced non-small cell lung cancer that has not been treated before. Participants must have high levels of a protein called PD-L1 on their tumors. The main goal is to check the safety of these drug comb…

This study compares a new drug, depemokimab, to an existing one, mepolizumab, in adults with a rare inflammatory disease called EGPA. The goal is to see if depemokimab can help patients achieve and maintain remission (no symptoms and low steroid use) over 52 weeks. Participants m…

This study looks at the long-term safety of a drug called linerixibat for people with primary biliary cholangitis (PBC) who suffer from severe itching. About 242 adults who have already taken linerixibat in earlier studies will continue taking it to see how safe it is over time. …

This study is the first time a new drug, GSK4347859, is being tested in humans. The goal is to see if it is safe and how the body processes it. It involves 65 healthy volunteers and is currently on hold. The drug is being developed for lupus, an autoimmune disease.

This study is the first time GSK4528287, a drug for inflammatory bowel diseases like ulcerative colitis, is being given to humans. It involves 48 healthy volunteers who receive a single dose to check for side effects, measure drug levels in the blood, and see how the drug works i…

This study was designed to see how the drug belantamab mafodotin behaves in people with multiple myeloma who also have liver problems. It would have compared patients with different levels of liver function to those with normal livers. However, the study was withdrawn before enro…

This study looks at the safety of the shingles vaccine (HZ/su) in pregnant women aged 18-49 with weakened immune systems. It compares rates of major birth defects and other infant health problems between vaccinated and unvaccinated women. The goal is to gather real-world safety d…